Greg Bradley - 26 Apr 2023 Form 4 Insider Report for Petros Pharmaceuticals, Inc. (PTPI)

Role
Director
Signature
/s/ Mitchell Arnold, attorney-in-fact
Issuer symbol
PTPI
Transactions as of
26 Apr 2023
Net transactions value
$0
Form type
4
Filing time
28 Apr 2023, 18:03:08 UTC
Previous filing
12 Apr 2023
Next filing
26 Dec 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PTPI Common Stock Options Exercise +6,050 +267% 8,314 26 Apr 2023 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PTPI Restricted Stock Units Options Exercise $0 -6,050 -100% $0.000000* 0 26 Apr 2023 Common Stock 6,050 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On November 30, 2022, Petros Pharmaceuticals, Inc. effected a 1-for-10 reverse stock split of its common stock (the "Reverse Stock Split"), effective as of 4:05 p.m., New York time. All share amounts reported herein have been adjusted to give effect to the Reverse Stock Split.
F2 On April 7, 2022, the reporting person was granted 6,050 restricted stock units, vesting on April 7, 2023, subject to the reporting person's employment on that date. Such restricted stock units were converted into common stock on a one-for-one basis (after adjusting for the Reverse Stock Split) on April 26, 2023.
F3 Each restricted stock unit represents the right to receive, at settlement, one share of common stock of the Issuer.